Impact factor mania and publish-or-perish may have contributed to Dana-Farber retractions, experts sayLearning from past errors (and misconduct) in cancer research February 02, 2024Vol.50 No.05By Jacquelyn Cobb
Dana-Farber to retract six papers, correct 31, over “image discrepancies” in papers co-authored by top leaders January 26, 2024Vol.50 No.04By Jacquelyn Cobb
News Analysis Dana-Farber’s bold split from the Brigham is a culmination of Boston oncology’s complicated history December 08, 2023Vol.49 No.45By Jacquelyn Cobb
In Brief Mark Agnel Frederick Dawson, Cigall Kadoch, Michelle Monje receive MSK’s 2023 Paul Marks Prize November 17, 2023Vol.49 No.43
In Brief Elad Sharon named clinical and translational director of Immunotherapy Toxicity Service at Dana-Farber October 27, 2023Vol.49 No.40
In Brief Sylvester, DFCI researchers receives $4M NCI grant to study whether lifestyle interventions can benefit patients with advanced breast cancer October 20, 2023Vol.49 No.39
In Brief Dana-Farber, Beth Israel Deaconess plan to build free-standing inpatient cancer hospital September 15, 2023Vol.49 No.34
In Brief Sylvester, Dana-Farber researchers receive $7M from PCORI to study diet, exercise effects on mental and physical functioning in older cancer survivors July 21, 2023Vol.49 No.29
Clinical Roundup Study finds a cause of resistance to revumenib in acute leukemia March 17, 2023Vol.49 No.11
In Brief Dana-Farber, Gladstone Institutes join Parker Institute network September 30, 2022Vol.48 No.35
